Journal Article Summary
The article reviews levomilnacipran (LVM), a newly approved medication for major depressive disorder (MDD), highlighting its unique properties as a dual neurotransmitter reuptake inhibitor. Unlike other antidepressants, LVM primarily inhibits norepinephrine reuptake more than serotonin, which may offer advantages for patients who do not respond well to traditional treatments. This topic is significant because many individuals with MDD struggle to find effective treatments, and LVM could provide a new option for those who have not had success with existing medications.
The authors analyzed data from several clinical trials involving LVM, including five short-term studies and two long-term studies. In the short-term trials, LVM was more effective than a placebo in reducing depression symptoms and improving daily functioning. However, in the long-term study, while LVM showed some benefits, it did not significantly outperform the placebo in preventing relapse. The medication was generally well tolerated, with common side effects including nausea, headache, and dry mouth, and a slightly higher rate of discontinuation due to adverse effects compared to placebo.
Despite its potential benefits, the review notes several limitations, including the lack of long-term efficacy data and the need for further studies to determine LVM's effectiveness in specific subgroups of patients. Patients should be aware of possible side effects, particularly cardiovascular effects like increased blood pressure and heart rate, and should discuss these with their healthcare provider. It is essential for individuals considering LVM to have a thorough conversation with their doctor about their medical history and any potential risks associated with this medication.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Asnis Gregory M, Henderson Margaret A. Levomilnacipran for the treatment of major depressive disorder: a review. Neuropsychiatric Disease and Treatment 2015. DOI: 10.2147/NDT.S54710. PMID: 25657584. PMCID: PMC4295915.
Featured Pill Pals Product
Desvenlafaxine Succinate Extended Release 50 mg Tablets --- 30 Count --- Generic for Pristiq --- Slate Run Pharma
Desvenlafaxine Succinate Extended Release 50 mg Tablets — 30 Count — Generic for Pristiq — Slate Run Pharma is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
